Omeros

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Omeros reports record earnings, navigates FDA challenges for growth

Omeros showcased strong financial performance, a robust pipeline, and strategic partnerships in Q4 2022.
While challenges like FDA concerns and tight timelines exist, the company is well-positioned to capitalize on growth opportunities.
With a focus on advancing key programs and maintaining financial stability, Omeros aims to deliver value to shareholders and patients.

Omeros reports Q1 loss, progresses in key programs amid challenges

Omeros' Q1 2023 performance reflected a shift from net income to a significant loss, driven by increased expenses and reduced income, while maintaining a strong cash position and positive sales figures for OMIDRIA.
The company showcased strengths in diversified revenue streams, progress in key clinical programs, and inclusion in the Russell 3000 Index, signaling growth potential and market recognition.
Challenges in regulatory processes, market competition, and resource allocation were evident, requiring strategic navigation and operational efficiency to overcome hurdles and drive future success.
Amidst challenges, Omeros identified opportunities in expanding royalties, advancing clinical programs, exploring new indications, and leveraging immuno-oncology advancements to drive future growth and innovation.

Omeros reports Q2 loss, eyes FDA decisions and revenue growth

Omeros faces challenges with debt maturity and regulatory approvals but benefits from strong revenue streams
The company's pipeline shows promise in addressing various diseases, with a focus on high unmet medical needs
Opportunities lie in expanding revenue through OMIDRIA and advancing key drug candidates towards approval

Omeros reports Q3 losses, highlights pipeline strength and regulatory progress

Omeros demonstrated a mixed financial performance in Q3 2023 but showcased strength in its pipeline and strategic alignment with regulatory authorities.
Challenges persist in financial metrics and regulatory timelines, necessitating a balance between innovation and operational efficiency.
The company's opportunities in immuno-oncology and stable revenue streams position Omeros for future growth and impact in the biopharmaceutical landscape.

Omeros extends cash runway, advances key pipeline candidates for growth

Omeros demonstrated improved financial performance, securing additional funding and advancing key pipeline candidates, positioning the company for future growth.
While facing challenges in regulatory processes and anticipated losses, Omeros' strategic priorities and innovative pipeline offer opportunities for long-term success.
Management's focus on financial stability, operational efficiency, and product differentiation underscores Omeros' commitment to delivering value to shareholders and patients.

Omeros reports increased net loss but optimistic about pipeline progress

Omeros faced a significant increase in net loss in Q1 2024 but maintains a strong financial position with $230.3 million in cash and investments.
The company's development programs, especially OMS906, show promise with positive trial results and potential milestone payments tied to OMIDRIA sales.
While challenges like regulatory approvals and competition exist, Omeros is optimistic about its pipeline and aims for Phase III trials and regulatory successes.
Overall, Omeros is strategically positioned to leverage opportunities for growth and diversification in the biopharmaceutical market.

Omeros reports improved Q3 performance with promising drug developments

Omeros' Q3 2024 performance showed improvements in net loss and strategic financial decisions.
The company's strengths lie in potential revenue streams from OMIDRIA sales and positive trial data.
Challenges include regulatory hurdles and managing costs amidst multiple development programs.
Opportunities exist in sales growth, milestone payments, and advancing key drug development programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arrival Group

Bank of Hawaii

Harrow Health Inc

PAR Technology

Theravance Biopharma

Trupanion

While the concept of short-squeeze stocks has been all the rage throughout most of the pandemic-disruption cycle, we may have been doing this all wrong. Rather, it's time to address this speculative practice under a three-dimensional lens.

7 Short-Squeeze Stocks That Are Screaming for Speculation

Omeros Corporation focuses on small-molecule and antibody drugs for common disorders and rare diseases. The company has prioritized the resubmission of its BLA for Narsoplimab for TA-TMA treatment and is advancing Phase-3 clinical trials for MASP-3 inhibitor OMS906. Narsoplimab holds promise for treating TA-TMA, COVID-19, and Lupus Nephritis but faces competition in the latter two conditions.

Omeros: Why It Is Worthwhile To Bet On Narsoplimab

Omeros Corporation (NASDAQ:OMER ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman & Chief Executive Officer Mike Jacobsen - Chief Accounting Officer Catherine Melfi - Chief Regulatory Officer Steve Whitaker - Vice President-Clinical Development Andreas Grauer - Chief Medical Officer Conference Call Participants Steve Brozak - WBB Securities Serge Belanger - Needham Operator Good afternoon, and welcome to today's earnings call for Omeros Corporation. At this time, all participants are in a listen-only mode.

Omeros Corporation (OMER) Q3 2023 Earnings Call Transcript

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2023, which inc.

Omeros Corporation Reports Third Quarter 2023 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2023, on Thursday, November 9, 2023, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the co.

Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced online publication of a report detailing treatment with narsoplimab of 15 adult and pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), 14 of whom had “high-risk” TA-TMA. Narsoplimab is Omeros' investigational antibody targeting MASP-2, the effector enzyme of the lectin pathway of the complement system. The report was authored by an external group of investigators i.

Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Andreas Grauer, M.D., has been named Omeros' chief medical officer. In his new role, Dr. Grauer will be responsible for guiding all clinical activities globally for the company, including clinical development and operations, medical affairs, safety, and biometrics. A highly tenured physician, scientist and pharmaceutical leader, Dr. Grauer brings to Omeros over 20 years of industry experience across a broad range o.

Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

Omeros Corp said on Monday it will discontinue a trial studying its therapy to treat a type of kidney disease after it failed to meet the main goal of the late-stage study.

Omeros to terminate kidney disease trial as therapy fails late-stage study

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today provided an update regarding the interim analysis outcome in ARTEMIS-IGAN, the Company's Phase 3 trial evaluating narsoplimab for t.

Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy

Omeros' "Buy" stance is based on upcoming developments in the second half of 2023-2024 around narsoplimab. OMER is expected to present a detailed analysis strategy for the narsoplimab BLA's reapplication for HSCT-TMA, leading to a potential PDUFA by mid-2024. The phase 3 ARTEMIS-IGAN trial in 3Q23 will assess narsoplimab's efficacy in treating IgA nephropathy. We believe the data will be positive.

Omeros: Betting Big On Narsoplimab, We Are Still A Buyer

Omeros Corporation (NASDAQ:OMER ) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Jennifer Williams - IR Gregory Demopulos - Co-Founder, Chairman, CEO & President Michael Jacobsen - CAO, VP, Finance & Treasurer Nadia Dac - VP & Chief Commercial Officer Catherine Melfi - Chief Regulatory Officer & VP, Regulatory Affairs and Quality Systems Conference Call Participants Colin Bristow - UBS Stephen Brozak - WBB Securities Gregory Harrison - Bank of America Merrill Lynch Serge Belanger - Needham & Company Operator Good morning, and welcome to today's earnings call for Omeros Corporation. [Operator Instructions].

Omeros Corporation (OMER) Q2 2023 Earnings Call Transcript

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2023, which include.

Omeros Corporation Reports Second Quarter 2023 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2023, on Wednesday, August 9, 2023, before the market opens. Omeros management will host a conference call and webcast that same day at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conferen.

Omeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023

Omeros Corporation's share price has seen significant run-ups in recent months despite disappointing first quarter results in 2023 and the company's lack of profitability. The company was awarded $6.69 million from the National Institute on Drug Abuse for its program OMS527, which focused on the treatment of cocaine use disorder. However, it also has $344 million in long-term debts. Omeros' future heavily relies on FDA approval of its drug candidates, particularly Narsoplimab, and faces intense competition in the biopharmaceutical sector.

Omeros Corporation - Still Looking Too Risky For A Buy Rating

The company's lead therapy, Narsoplimab, has not yet been approved. As of the first quarter, Omeros had $371.4 million in cash.

Why Shares of Omeros Dropped on Monday

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the slides presented yesterday in the “late-breaker” session at the 2023 European Hematology Association (EHA) Congress in Frankfurt, Germany are now available on Omeros' website. The presentation, which details data from a pre-specified interim analysis from the ongoing Phase 1b clinical trial of Omeros' lead MASP-3 inhibitor OMS906 in complement-inhibitor-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH.

Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that data from a pre-specified interim analysis of its ongoing Phase 1b clinical trial of OMS906, the company's lead MASP-3 inhibitor, in complement-inhibitor-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening hemolytic blood disorder, will be shared at the 2023 European Hematology Association (EHA) Congress in Frankfurt, Germany. Identified as one of the top five late-breaking subm.

Omeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congress

HSCT-TMA BLA Resubmission: Omeros plans to resubmit a BLA for narsoplimab, potentially gaining approval by Q2 2024. IgAN Trial Progress: Top-line results for the phase 3 ARTEMIS trial on narsoplimab for IgAN are expected in Q3 2023.

Omeros: Q1 Earning Overview, Best Contrarian Biotech Play Of 2023

Omeros Corporation (NASDAQ:OMER ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman and CEO Mike Jacobsen - Chief Accounting Officer Nadia Dac - Chief Commercial Officer Cathy Melfi - Chief Regulatory Officer Steve Whitaker - Chief Medical Officer Conference Call Participants Steve Brozak - WBB Securities Greg Harrison - Bank of America Elliott Bosco - UBS Brandon Folkes - Cantor Fitzgerald Operator Good afternoon, and welcome to today's earnings call from Omeros Corporation. At this time, all participants are in a listen-only mode.

Omeros Corporation (OMER) Q1 2023 Earnings Call Transcript

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2023, which include.

Omeros Corporation Reports First Quarter 2023 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2023, on Tuesday, May 9, 2023, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details To access the live conference call via phone.

Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced positive results from a pre-specified interim analysis of its ongoing Phase 1b clinical trial of OMS906, the company's lead MASP-3 inhibitor, in complement-inhibitor-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening hemolytic blood disorder. Statistically significant and clinically meaningful improvements were observed in all measured markers of hemolysis, including hemoglobin (Hgb.

Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to develop Omeros' lead orally administered compound from its proprietary phosphodiesterase 7 (PDE7) program OMS527 for the treatment of cocaine use disorder (CUD). The grant is expected to provide $6.

Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program

Hyperfine

Lantheus Holdings

Here we discuss three stocks - LNTH, OMER and HYPR - that have been creating wealth for their investors in 2023 even though several competitors faltered amid macro challenges. Will the trend continue?

3 Medical Stocks Creating Wealth Despite Macro Challenges

Omeros Corporation (NASDAQ:OMER ) Q4 2022 Earnings Conference Call March 13, 2023 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Dr. Greg Demopulos - Chairman and CEO Mike Jacobsen - Chief Accounting Officer Cathy Melfi - Chief Regulatory Officer Steve Whitaker - Chief Clinical Officer Nadia Dac - Vice President and CCO Conference Call Participants Colin Bristow - UBS Steve Brozak - WBB Securities Mary Kate - Bank of America Brandon Folkes - Cantor Serge Belanger - Needham & Company Operator Good afternoon. And welcome to today's earnings call from Omeros Corporation.

News for Omeros Stock (OMER)